Publication number: 20160159814
Abstract: The present invention provides novel compounds of formula [I] or pharmaceutically acceptable salts thereof: which are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.
Type:
Application
Filed:
July 25, 2014
Publication date:
June 9, 2016
Applicant:
TAISHO PHARMACEUTICAL CO., LTD.
Inventors:
Daisuki WAKASUGI, Hiroshi OHTA, Kumiko OKADA, Shin-ichi SHIROKAWA, Minoru MORIYA, Tomoko TAMITA, Kumi ABE, Nobutaka HATTORI, Yuko ARAKI
Publication number: 20160130278
Abstract: The present invention provides novel compounds of formula [IA] or pharmaceutically acceptable salts thereof: which are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.
Type:
Application
Filed:
June 9, 2014
Publication date:
May 12, 2016
Applicant:
TAISHO PHARMACEUTICAL CO., LTD
Inventors:
Yousuke YAMADA, Hiroshi OHTA, Tomoko TAMITA, Kumi ABE, Shuji YAMAMOTO, Shin-ichi SHIROKAWA, Masahito ABE, Yohei MATSUDA, Yuko ARAKI
Patent number: 9193695
Abstract: The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.
Type:
Grant
Filed:
September 30, 2011
Date of Patent:
November 24, 2015
Assignee:
TAISHO PHARMACEUTICAL CO., LTD.
Inventors:
Takeshi Kuwada, Mitsukane Yoshinaga, Tomoko Ishizaka, Daisuke Wakasugi, Shin-ichi Shirokawa, Nobutaka Hattori, Youichi Shimazaki, Naoki Miyakoshi
Publication number: 20130197217
Abstract: The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.
Type:
Application
Filed:
September 30, 2011
Publication date:
August 1, 2013
Applicant:
TAISHO PHARMACEUTICAL CO., LTD
Inventors:
Takeshi Kuwada, Mitsukane Yoshinaga, Tomoko Ishizaka, Daisuke Wakasugi, Shin-ichi Shirokawa, Nobutaka Hattori, Youichi Shimazaki, Naoki Miyakoshi